Table 2. Antibiotic Hybrid Molecules Currently under Clinical Development.
| compound | antibiotic 1 inhibited process 1 | antibiotic 2 inhibited process 2 | stage | ref |
|---|---|---|---|---|
| cadazolid | quinolone topoisomerases II and IV | oxazolidinone translation | phase III | (122) |
| cefilavancin (TD-1792) | vancomycin lipid II | cephalosporin PBPs | phase III | (123) |
| DNV3837 (MCB-3681)a | fluoroquinolone topoisomerases II and IV | oxazolidinone translation | phase II | (124) |
| TNP-2092 (CBR-2092) | rifamycin RNA polymerase | quinolone topoisomerases II and IV | phase II | (120) |
| TD-1607 | glycopeptide lipid II | cephalosporin PBPs | phase I | (125) |
a
MCB-3681 was developed into the prodrug MBB-3837, which was renamed DNV3837 after Morphochem was acquired by Deinove.